Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients. What do 676 primary and recurrent ovarian cancer (OC) patients expect from ...
In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of ...
Developed as a predictive biomarker, the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The new test ...
In this final of four exclusive episodes, MedPage Today brought together three expert leaders for a virtual discussion on antibody-drug conjugates (ADCs) in ovarian cancer. Moderator Susana Campos, MD ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in ...
TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback